🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the infection, according to health experts.

An International Public Health Issue

Gonorrhoea infections are increasing worldwide, with estimates suggesting in excess of 82 million infections annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs currently available.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance found that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to develop it.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Clinical Trial Results and Global Access

Based on results detailed in a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which involves an injection and a pill. The study involved hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced positive views. The availability of a single-dose, oral treatment of this kind is seen as a "game-changer" for managing the epidemic. This is viewed as essential to reduce the burden of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.